Skip to main content
. 2016 Oct;12(10):609–616.

Table 2.

Recommended Treatment Options for the First Episode of CDIa

Recommended Therapy Dose/Schedule Comment(s)
Metronidazole Mild CDI: 500 mg 3 times daily for 10 days (PO or IV)
  • Less effective than other options for treating CDI

  • Only used in the mildest cases and only via IV route if the patient is unable to take oral medications

Vancomycin Mild to severe cases: 125 mg 4 times daily for 10-14 days PO
  • Superior to metronidazole for moderate to severe CDI

  • Increases the risk of VRE89

Severe complicated cases: 250-500 mg 4 times daily. Consider 500 mg of vancomycin in 100 mg normal saline per rectum every 6 hours as a retention enema in the face of ileus.
Fidaxomicin All forms of CDI: 200 mg PO twice daily for 10 days
  • Lower rate of recurrence than other treatments

  • Less likely than vancomycin to promote acquisition of VRE25

  • More expensive than other treatments

Tigecycline Refractory cases of CDI: 100 mg IV, then 50 mg IV twice daily
  • Not approved for treatment

  • Can be used as rescue treatment for patients with severe CDI when treatment with vancomycin and metronidazole fails29

Nitazoxanide All forms of CDI: 500 mg PO twice daily for 10 days
  • Not approved for treatment

  • In preliminary study, as effective as metronidazole or vancomycin31,32

  • More studies are needed.

Rifaximin All forms of CDI: 400-550 mg twice daily for 14 days
  • Not approved for treatment

  • Has been used with tigecycline with or without vancomycin for refractory cases of CDI36,37

  • More studies are needed.

Colonic surgery (colectomy or colon bypass) Indicated with shock, respiratory failure, lactate levels >5 mmol/L, signs of end organ damage. Associated with refractory CDI and fulminant colitis.
  • Colon-sparing approach has been described in the literature to reduce mortality and preserve the colon.

a

Initial antibiotics causing CDI should be stopped if possible, and patients should be hydrated.

CDI, Clostridium difficile infection; IV, intravenous; PO, oral; VRE, vancomycin-resistant enterococci.